France
· Delayed Price · Currency is EUR MaaT Pharma Statistics
Total Valuation
MaaT Pharma has a market cap or net worth of EUR 109.68 million. The enterprise value is 95.70 million.
| Market Cap | 109.68M |
| Enterprise Value | 95.70M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MaaT Pharma has 13.92 million shares outstanding. The number of shares has increased by 13.16% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 13.92M |
| Shares Change (YoY) | +13.16% |
| Shares Change (QoQ) | +5.14% |
| Owned by Insiders (%) | 1.69% |
| Owned by Institutions (%) | 0.08% |
| Float | 3.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 36.46 |
| PB Ratio | 4.28 |
| P/TBV Ratio | 4.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.96 |
| EV / Sales | 37.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.05 |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 0.67.
| Current Ratio | 2.76 |
| Quick Ratio | 2.61 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.91 |
| Interest Coverage | -47.94 |
Financial Efficiency
Return on equity (ROE) is -84.85% and return on invested capital (ROIC) is -34.70%.
| Return on Equity (ROE) | -84.85% |
| Return on Assets (ROA) | -29.99% |
| Return on Capital (ROIC) | -34.70% |
| Revenue Per Employee | 47,611 |
| Profits Per Employee | -447,000 |
| Employee Count | 60 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 8.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.29% in the last 52 weeks. The beta is 0.20, so MaaT Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | +19.29% |
| 50-Day Moving Average | 7.68 |
| 200-Day Moving Average | 7.87 |
| Relative Strength Index (RSI) | 49.88 |
| Average Volume (20 Days) | 3,894 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MaaT Pharma had revenue of EUR 2.57 million and -24.14 million in losses. Loss per share was -2.03.
| Revenue | 2.57M |
| Gross Profit | 1.44M |
| Operating Income | -24.16M |
| Pretax Income | -24.14M |
| Net Income | -24.14M |
| EBITDA | -23.94M |
| EBIT | -24.16M |
| Loss Per Share | -2.03 |
Balance Sheet
The company has 31.15 million in cash and 17.17 million in debt, giving a net cash position of 13.98 million or 1.00 per share.
| Cash & Cash Equivalents | 31.15M |
| Total Debt | 17.17M |
| Net Cash | 13.98M |
| Net Cash Per Share | 1.00 |
| Equity (Book Value) | 25.61M |
| Book Value Per Share | 1.84 |
| Working Capital | 25.93M |
Cash Flow
In the last 12 months, operating cash flow was -18.20 million and capital expenditures -740,000, giving a free cash flow of -18.94 million.
| Operating Cash Flow | -18.20M |
| Capital Expenditures | -740,000 |
| Free Cash Flow | -18.94M |
| FCF Per Share | -1.36 |
Margins
| Gross Margin | 56.01% |
| Operating Margin | -939.87% |
| Pretax Margin | -938.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MaaT Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.16% |
| Shareholder Yield | -13.16% |
| Earnings Yield | -25.75% |
| FCF Yield | -17.27% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaaT Pharma has an Altman Z-Score of 0.86. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.86 |
| Piotroski F-Score | n/a |